Mohamed S. Albannan

Mohamed S. Albannan

Auto-generated profile, based on publicly available information

Mohamed S. Albannan

Biotechnology Research Center, New Damietta, Egypt

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Annals of Hepatology
Verified
Journal Article
Open access
AAAbdelfattah M. Attallah
Abdelfattah M. Attallah
MEMohamed El-Far
Mohamed El-Far
CMCamelia A. Abdel Malak
Camelia A. Abdel Malak
MOMohamed Omran
Mohamed Omran
KFKhaled Farid
Khaled Farid
MNMohamed A. El Naggar
Mohamed A. El Naggar
Background and rationale for the study. Continuing search for suitable tumor-markers is of clinical value in managing patients with various malignancies. These markers may be presented as intracellular substances in tissues or may be released into the circulation and appear in serum. Therefore, this work is concerned with identification and quantitative determination of epithelial membrane antigen (EMA) and fibronectin and estimating their performances as surrogate markers for identifying hepatocellular carcinoma (HCC). A total of 627 individuals constituted this study [fibrosis (F1-F3) = 217; cirrhosis = 191; HCC = 219]. Western-blot was used for identifying EMA and fibronectin in sera. As a result, a single immunoreactive band was shown at 130-kDa and 90-kDa corresponding to EMA and fibronectin, respectively. They were quantified using ELISA providing values in HCC higher than fibrosis or cirrhosis with a significant difference (P < 0.0001). For identifying HCC, EMA showed 0.82 area under receiver-operating characteristic curve (AUC) with sensitivity = 70% and specificity = 78% while fibronectin yielded AUC = 0.70 with sensitivity = 67% and specificity = 82%. FEBA-Test comprising fibronectin and EMA together with total-bilirubin and AFP was constructed yielding AUC = 0.92 for identifying HCC from cirrhosis with sensitivity = 89% and specificity = 85%. FEBA-Test was then tested for differentiating HCC from fibrosis showing AUC = 0.97 with sensitivity = 90% and specificity = 89%. FEBA-Test enabled the correct identification of HCC patients with CLIP 0-1 and size ≤ 3 cm with AUC = 0.80 and AUC = 0.84, respectively, indicating its ability in identifying early HCC. A four-marker index may improve the early detection of HCC with a high degree of accuracy.

1 November 2012 in Clinica Chimica Acta
Verified
Journal Article
Closed access
AAAbdelfattah M. Attallah
Abdelfattah M. Attallah
MOMohamed M. Omran
Mohamed M. Omran
KFKhaled Farid
Khaled Farid
MEMahmoud El-Bendary
Mahmoud El-Bendary
TETarek M. Emran
Tarek M. Emran
IEIbrahim El-Dosoky
Ibrahim El-Dosoky

1 March 2015 in Annals of Hepatology
Verified
Journal Article
Open access
AAAbdelfattah M Attallah
Abdelfattah M Attallah
MEMohamed El-Far
Mohamed El-Far
CMCamelia A Abdel Malak
Camelia A Abdel Malak
MOMohamed Omran
Mohamed Omran
KFKhaled Farid
Khaled Farid
MAMohamed O Abdallah
Mohamed O Abdallah
BACKGROUND AND RATIONALE FOR THE STUDY: The assessment of liver fibrosis provides useful information not only for diagnosis but also for therapeutic decision. This study was concerned with determining the levels of collagen III and its degrading enzyme matrix metalloproteinase-1 (MMP-1) as direct and complementary markers for liver fibrosis staging. A total of 269 chronic hepatitis C patients constituted this study. Western blotting was used for identifying collagen III and MMP-1 in serum samples. As a result, collagen III and MMP-1 were identified, respectively, at 70 and 245 kDa using their respective mono-specific antibodies. These two markers were quantified in sera of patients using ELISA. Next, Fibro-check was constructed combining collagen III and MMP-1 together with other indirect markers which reflect alteration in hepatic functions that proved useful to stage liver fibrosis. Fibro-check produced area under the receiver-operating characteristic curve (AUC) 0.91 and 0.83 for significant (F2-F4) and cirrhosis (F4), respectively. Additionally, we estimated the performance of Fibro-check in comparison with aspartate to platelet ratio index (APRI) and fibrosis index. Fibro-check seems to be more efficient than both of them. Fibro-check was then applied to the validation study to test its accuracy and reproducibility showing AUCs 0.90 for F2-F4 and 0.86 for F4. Fibro-check combining 'direct' and 'indirect' markers using a mathematical formula may improve the staging of liver fibrosis with a high degree of accuracy and seems more efficient than APRI and Fibrosis index in this group of Egyptian patients.

4 March 2013 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Closed access
AAAbdelfattah M. Attallah
Abdelfattah M. Attallah
MEMohamed El‐Far
Mohamed El‐Far
MOMohamed M. Omran
Mohamed M. Omran
KFKhaled Farid
Khaled Farid
MAMohamed S. Albannan
Mohamed S. Albannan
IEIbrahim El‐Dosoky
Ibrahim El‐Dosoky

7 July 2022 in Veterinary World
Verified
Journal Article
Open access
MSMohamed Saadh
Mohamed Saadh
FLFeras Lafi
Feras Lafi
ADAdnan Ahmad Dahadha
Adnan Ahmad Dahadha
MAMohamed S. Albannan
Mohamed S. Albannan
Background and Aim: Clostridium perfringens type A is an anaerobic bacterium that produces four major toxins (alpha, beta, epsilon, and iota) that cause various diseases. Most of the important C. perfringens-associated diseases of farm animals are caused by alpha-toxin. This study aimed to produce a vaccine against alpha-toxin using C. perfringens type A (ATCC 13124) and investigate its potency, stability, and safety. Materials and Methods: The vaccine was formulated of its constituents for 1 h. Each milliliter of the final vaccine product contained alpha toxoid 15 lecithovitellinase activity (Lv) by adding (0.375 mL containing 40 Lv) and approximately 0.2 mL from 3% concentrated aluminum hydroxide gel, <0.001% W/V thiomersal, <0.05% W/V formaldehyde, and nearly 0.425 mL phosphate-buffered saline (pH 7.2). The vaccine efficacy was evaluated in rabbits and cattle by performing potency, stability, and safety tests. Results: The vaccine produced approximately 8.8 and 4.9 IU/mL neutralizing antibodies in rabbits and cattle, respectively. These concentrations were higher than the lowest concentration recommended by various international protocols and the United States Department of Agriculture by 2.20-fold in rabbits and 1.23-fold in cattle. Interestingly, the formulated vaccine enhanced immune responses by 1.80-fold in rabbits compared with that in cattle; the difference was statistically significant (p < 0.0001). The vaccine was stable for 30 months. In vaccinated rabbits, the body temperature slightly increased temporarily during the first 10 h of vaccination; however, the temperature difference was not statistically significant (p > 0.05). Conclusion: This study describes a manufacturing process to obtain sufficient amounts of a vaccine against C. perfringens alpha-toxin. The formulated vaccine effectively elicited a higher level of neutralizing antibody response than the international standards. Furthermore, the vaccine was found to be stable, safe, and effective in preventing C. perfringens-related diseases in rabbits and cattle. Further studies are necessary to evaluate the efficacy of this vaccine in other farm animals.

30 August 2017 in British Journal of Biomedical Science
Verified
Journal Article
Closed access
AAAm Attallah
Am Attallah
DOD Omran
D Omran
MOMohamed Omran
Mohamed Omran
MAM. S. Albannan
M. S. Albannan
RZRania Zayed
Rania Zayed
AYA Yosry
A Yosry
Background: Fibrosis markers are useful for the prediction of cirrhosis but clinical scores such as King’s score, AST-Platelet ratio index (APRI), Biotechnology research center (BRC), Fibrosis routine test (FRT), Fibro-α score and Fibro-quotient (FibroQ) have limited accuracy for diagnosing significant fibrosis. We hypothesised that new markers (reflecting the balance between hepatic fibrogenesis and fibrolysis) together with other indirect fibrosis markers would together construct a more sensitive and specific score capable of identifying fibrosis than existing scores. Methods: Collagen IV, hyaluronic acid, platelet-derived growth factor (PDGF) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were measured by ELISA, and AST, ALT, platelet count, albumin, total bilirubin, INR and AFP by routine methods in 148 patients with hepatitis C induced liver disease. Stepwise linear discriminant analysis and area under receiver-operating characteristic curves (AUCs) were used to create a predictive score and compare it to others. Results: Patients with significant fibrosis (n = 100, F2–F4) showed 2.08, 2.14, 1.80 and 1.90-fold increase in collagen IV, hyaluronic acid, PDGF and TIMP-1, respectively, over patients with no or mild fibrosis (n = 48, F0/F1)(all p < 0.01). Significant independent predictors of F2–F4 were AFP (AUC 0.79), age (0.76), PDGF (0.74), collagen IV (0.78) and TIMP (0.75), which together formed a five-marker score ‘Fibro-Mark’ for predicting F2–F4. In comparison with other scores, AUC for Fibro-Mark was 0.89, BRC was 0.83, followed by FRT and King’s score (both 0.82), APRI (0.80), Fibro-α (0.70) and finally Fibro Q (0.63). Conclusions: The Fibro-Mark score provides better discrimination in hepatic-fibrosis staging in chronic hepatitis C patients than existing scores.